Balyasny Asset Management LLC Arbutus Biopharma Corp Transaction History

Balyasny Asset Management LLC

  • $54.8 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$1.91 - $2.85 $4,553 - $6,794
2,384 Added 19.46%
14,633 $34,000
Q3 2022

Nov 14, 2022
BUY
$1.88 - $2.88 $23,028 - $35,277
12,249 New
12,249 $23,000
Q2 2021

Aug 16, 2021
SELL
$2.5 - $3.51 $30,367 - $42,635
-12,147 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$3.14 - $4.84 $38,141 - $58,791
12,147 New
12,147 $40,000

Others Institutions Holding ABUS

# of Institutions
130
Shares Held
82.2M
Call Options Held
4.82M
Put Options Held
546K
View Full List

About Arbutus Biopharma Corp

ABUS Quotes by TradingView
  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $468M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email